Skip to main content
Clinical Trials/NCT03218436
NCT03218436
Completed
Not Applicable

Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia

University Hospital Tuebingen1 site in 1 country63 target enrollmentStarted: September 1, 2017Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
63
Locations
1
Primary Endpoint
Pathological remission of cervical intraepithelial neoplasia

Overview

Brief Summary

Cervical intraepithelial neoplasia will be treated with physical low temperature plasma in the plasma cohort compared to watchful waiting in the control cohort.

Primary endpoint after 3-6 months: Pathological remission.

Secondary endpoint: HPV remission.

Detailed Description

The study was completed with Less recruitment as it was planned due to overwhelming study success. The study was published in August 2023. A link has been added to the Reference section.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Histologically confirmed CIN III
  • Not fully visible transformation zone
  • An indication of invasive disease
  • Expected lack of compliance of the patient or incapacity of the patient to understand the meaning and purpose of the clinical trial
  • Severe cardio-vascular disease
  • Lack of patient consent

Outcomes

Primary Outcomes

Pathological remission of cervical intraepithelial neoplasia

Time Frame: 3-6 months

Biopsy, Histopathological examination

Secondary Outcomes

  • Human papilloma virus remission rate(3-6 months)
  • Comfort / Dyscomfort during intervention(Immediately, 2 week, 3-6 months)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials